CasInvent Pharma

CasInvent Pharma was established in 2020 as a spin-off of Masaryk University (MU) in cooperation with the investment partner i&i Prague, s.r.o. (Ltd). The company's mission is to develop new therapeutic options for the treatment of resistant tumors. Its platform is based on proprietary, best-in-class highly selective inhibitors of enzymes belonging to the Casein Kinase 1 (CK1) family, which are responsible for regulating cellular mechanisms leading to resistance to targeted therapies. The CK1 inhibitors were discovered by research groups of professors Vítězslav Bryja and Kamil Paruch at the Faculty of Science of MU. The candidate compound is planned to enter clinical trials for resistant Acute Myeloid Leukemia (AML) and solid tumor indications such as PDAC, TNBC, Melanoma, or prostate cancer.

CasInvent Pharma was established in 2020 as a spin-off of Masaryk University (MU) in cooperation with the investment partner i&i Prague, s.r.o. (Ltd). The company's mission is to develop new therapeutic options for the treatment of resistant tumors. The CasInvent platform is based on the use of proprietary, best-in-class highly selective inhibitors of enzymes belonging to the Casein Kinase 1 (CK1) family. The CK1 inhibitors were discovered by the research groups of professors Vítězslav Bryja and Kamil Paruch at the Faculty of Science of MU. The candidate compound is planned to enter clinical trials focused on the treatment of resistant Acute Myeloid Leukemia (AML) and solid tumor indications such as PDAC, TNBC, Melanoma or prostate cancer.

1. CASINVENT - Highly Potent and Selective Inhibitors of CK1 Kinases
2. CASINVENT - Highly Potent and Selective Inhibitors of CK1 Kinases
3. CasInvent Pharma